Bulls Show Continued Momentum

July 26, 2021 By: adminbackup

The stock market was mostly higher on Friday following the June jobs report with another round of record highs for Tech and the broader market. Specifically, non-farm payrolls rose by 850,000, the sixth-straight monthly gain, versus forecasts for a print of 720,000. The unemployment rate, however, unexpectedly ticked up to 5.9% versus expectations for a dip to 5.6%. The small-caps failed to show...

Continue reading >>

Bitcoin tops $39,000 for the first time in nearly 6 weeks, adding $114 billion to the crypto market

By: adminbackup

...

Continue reading >>

Bulls Push Fresh all-Time Highs

July 25, 2021 By: adminbackup

The stock market was mostly higher on Friday following the June jobs report with another round of record highs for Tech and the broader market. Specifically, non-farm payrolls rose by 850,000, the sixth-straight monthly gain, versus forecasts for a print of 720,000. The unemployment rate, however, unexpectedly ticked up to 5.9% versus expectations for a dip to 5.6%. The small-caps failed to show...

Continue reading >>

Treasury yields climb, 10-year Treasury tops 1.28% ahead of PMI data

July 23, 2021 By: adminbackup

...

Continue reading >>

Bulls Stay Strong Despite Sluggish Session

By: adminbackup

The stock market showed continued strength on Wednesday following upbeat earnings from two blue-chips companies along with a rise in yields. Specifically the 10-year Treasury yield rose to nearly 1.3% after tapping a five-month low on Monday while stabilizing on Tuesday.The drop in rates caught Wall Street by surprise and remains a possible sign of a slowing economy due to the new coronavirus...

Continue reading >>

Extreme Option Profits Chart of Day… Pfizer (PFE)

July 22, 2021 By: adminbackup

Oversold, OCGN is gaining momentum. According to Tip Ranks, “Ocugen has inked a deal with India-based Bharat Biotech for the US rights for the company’s vaccine COVAXIN. And Bharat has now reported positive second interim analysis results from the COVAXIN Phase 3 trials. The vaccine displayed an overall efficacy rate of 78%, with 100% success against severe cases of the disease. COVAXIN...

Continue reading >>
Person with arms crossed

How $100 a Month Can Grow into $159,069 — Let Us Show You How!

Get Immediate Access And This Week's Buy Alerts!




Thank you! You're in. Check your email for access.
By registering you are agreeing to our Privacy Policy